Literature DB >> 9604186

Long-term health and employment outcomes of occupational asthma and their determinants.

T H Gassert1, H Hu, K T Kelsey, D C Christiani.   

Abstract

Occupational asthma is common, yet little is known about long-term outcomes in the United States. A case series of 55 (of 72) occupational asthma patients were interviewed in follow-up 31 (+/- 15) months after removal from the cause to evaluate asthma severity and employment outcomes. Standard criteria were used to rate severity. At follow-up, 54 subjects (98%) had active asthma, of which 26 cases (47%) were "severe." Multivariate analysis showed increased risk of "severe" asthma for women (odds ratio [OR] = 13.8; 95% confidence interval [95% CI] = 1.3 to 151.7) and industrial sector workers (OR = 11.9; 95% CI = 1.3 to 109.8). Thirty-eight subjects (69%) were unemployed, risk being greater for those with "severe" asthma (OR = 20.9; 95% CI = 1.9 to 229.8) and for those without a college degree (OR = 7.3; 95% CI = 1.2 to 43.4). These results indicate that occupational asthma is disabling and probably irreversible for most patients referred to a specialty clinic, despite prolonged removal from causative agents. Women, industrial workers, and those with severe asthma or lack of a college degree appear to be at risk for worse outcomes. Greater efforts at primary and secondary prevention should lessen the burden of long-term illness and unemployment due to occupational asthma.

Entities:  

Mesh:

Year:  1998        PMID: 9604186     DOI: 10.1097/00043764-199805000-00011

Source DB:  PubMed          Journal:  J Occup Environ Med        ISSN: 1076-2752            Impact factor:   2.162


  10 in total

1.  A descriptive study of work aggravated asthma.

Authors:  S K Goe; P K Henneberger; M J Reilly; K D Rosenman; D P Schill; D Valiante; J Flattery; R Harrison; F Reinisch; C Tumpowsky; M S Filios
Journal:  Occup Environ Med       Date:  2004-06       Impact factor: 4.402

2.  Surveillance for isocyanate asthma: a model based cost effectiveness analysis.

Authors:  D M Wild; C A Redlich; A D Paltiel
Journal:  Occup Environ Med       Date:  2005-11       Impact factor: 4.402

3.  Role of infections in the induction and development of asthma: genetic and inflammatory drivers.

Authors:  Qun Wu; Hong Wei Chu
Journal:  Expert Rev Clin Immunol       Date:  2009-01-01       Impact factor: 4.473

Review 4.  Occupational asthma.

Authors:  Nicholas J Kenyon; Brian M Morrissey; Michael Schivo; Timothy E Albertson
Journal:  Clin Rev Allergy Immunol       Date:  2012-08       Impact factor: 8.667

Review 5.  Outcome of occupational asthma after cessation of exposure: a systematic review.

Authors:  George Rachiotis; Rashna Savani; Andrew Brant; Stephanie J MacNeill; Anthony Newman Taylor; Paul Cullinan
Journal:  Thorax       Date:  2006-10-13       Impact factor: 9.139

6.  The frequency of workplace exacerbation among health maintenance organisation members with asthma.

Authors:  P K Henneberger; S J Derk; S R Sama; R J Boylstein; C D Hoffman; P A Preusse; R A Rosiello; D K Milton
Journal:  Occup Environ Med       Date:  2006-04-06       Impact factor: 4.402

7.  Occupational exposures associated with severe exacerbation of asthma.

Authors:  P K Henneberger; X Liang; L Lillienberg; A Dahlman-Höglund; K Torén; E Andersson
Journal:  Int J Tuberc Lung Dis       Date:  2015-02       Impact factor: 2.373

Review 8.  Predictors of delayed return to work or job loss with respiratory ill-health: a systematic review.

Authors:  Jean Peters; Simon Pickvance; Jane Wilford; Ewan Macdonald; Lindsay Blank
Journal:  J Occup Rehabil       Date:  2007-02-13

9.  Work life of persons with asthma, rhinitis, and COPD: a study using a national, population-based sample.

Authors:  Edward Yelin; Patricia Katz; John Balmes; Laura Trupin; Gillian Earnest; Mark Eisner; Paul Blanc
Journal:  J Occup Med Toxicol       Date:  2006-02-02       Impact factor: 2.646

Review 10.  Occupational asthma: a review.

Authors:  L J Lombardo; J R Balmes
Journal:  Environ Health Perspect       Date:  2000-08       Impact factor: 9.031

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.